Page last updated: 2024-11-06

3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID70588
CHEMBL ID2094583
CHEBI ID183381
SCHEMBL ID149565
SCHEMBL ID17257204
MeSH IDM0129669

Synonyms (63)

Synonym
EU-0001368
CBMICRO_025706
1,4-triazine, 5,6-diphenyl-3-(2-pyridinyl)-
1046-56-6
3-(2-pyridyl)-5,2,4-triazine
as-triazine,6-diphenyl-3-(2-pyridyl)-
nsc-242686
nsc242686
5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine
3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine
CHEMDIV1_019688
BIM-0025839.P001
3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine, >=99%
D1201
einecs 213-878-7
5,6-diphenyl-3-(2-pyridinyl)-1,2,4-triazine
as-triazine, 5,6-diphenyl-3-(2-pyridyl)-
brn 0542151
1,2,4-triazine, 5,6-diphenyl-3-(2-pyridinyl)-
nsc 242686
MAYBRIDGE1_007490 ,
SR-01000399497-2
AKOS001569955
STK835471
5,6-diphenyl-3-(pyridin-2-yl)-1,2,4-triazine
HMS562M10
HMS642O20
inchi=1/c20h14n4/c1-3-9-15(10-4-1)18-19(16-11-5-2-6-12-16)23-24-20(22-18)17-13-7-8-14-21-17/h1-14h
5,6-di(phenyl)-3-pyridin-2-yl-1,2,4-triazine
otmylobwdnftlo-uhfffaoysa-
CHEBI:183381
5,6-diphenyl-3-pyridin-2-yl-1,2,4-triazine
z9wp0m1oqu ,
unii-z9wp0m1oqu
5-26-12-00166 (beilstein handbook reference)
CCG-11535
FT-0613588
dndi1417275
CHEMBL2094583
SCHEMBL149565
DTXSID8061428
5,6-diphenyl-3-(2-pyridinyl)-1,2,4-triazine #
OTMYLOBWDNFTLO-UHFFFAOYSA-N
cambridge id 5557900
J-610077
bio7c7
SCHEMBL17257204
mfcd00006462
SR-01000399497-1
sr-01000399497
5,6-diphenyl-3-(2-pyridyl)-1,2 4-triazine
AS-64877
smssf-0005635
ams_cnc_id-117253909
3-(pyridin-2-yl)-5,6-diphenyl-1,2,4-triazine
pdt (ligand)
ferrotrace
5,6-diphenyl-3-(pyridin-2-yl)-as-triazine
ferroprint
BRD-K40497796-001-01-1
SB73251
D84148
CS-0095539
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,2,4-triazinesAny compound with a 1,2,4-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 2 and 4 of the core benzene ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationMyc proto-oncogene proteinHomo sapiens (human)
G1/S transition of mitotic cell cycleMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
branching involved in ureteric bud morphogenesisMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromatin remodelingMyc proto-oncogene proteinHomo sapiens (human)
intracellular iron ion homeostasisMyc proto-oncogene proteinHomo sapiens (human)
DNA damage responseMyc proto-oncogene proteinHomo sapiens (human)
response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
response to gamma radiationMyc proto-oncogene proteinHomo sapiens (human)
regulation of cell cycle processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
regulation of telomere maintenanceMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of stress-activated MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
protein-DNA complex disassemblyMyc proto-oncogene proteinHomo sapiens (human)
cellular response to UVMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
fibroblast apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of monocyte differentiationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of epithelial cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromosome organizationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of cell divisionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of telomerase activityMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription initiation by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
ERK1 and ERK2 cascadeMyc proto-oncogene proteinHomo sapiens (human)
response to growth factorMyc proto-oncogene proteinHomo sapiens (human)
cellular response to hypoxiaMyc proto-oncogene proteinHomo sapiens (human)
cellular response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of metanephric cap mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway by p53 class mediatorMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of miRNA transcriptionMyc proto-oncogene proteinHomo sapiens (human)
regulation of somatic stem cell population maintenanceMyc proto-oncogene proteinHomo sapiens (human)
regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
regulation of transcription by RNA polymerase IIN-myc proto-oncogene proteinHomo sapiens (human)
positive regulation of gene expressionN-myc proto-oncogene proteinHomo sapiens (human)
negative regulation of gene expressionN-myc proto-oncogene proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionN-myc proto-oncogene proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIN-myc proto-oncogene proteinHomo sapiens (human)
positive regulation of miRNA transcriptionN-myc proto-oncogene proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
core promoter sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
transcription coregulator bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
protein bindingMyc proto-oncogene proteinHomo sapiens (human)
identical protein bindingMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complex bindingMyc proto-oncogene proteinHomo sapiens (human)
protein dimerization activityMyc proto-oncogene proteinHomo sapiens (human)
E-box bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor bindingMyc proto-oncogene proteinHomo sapiens (human)
SCF ubiquitin ligase complex bindingMyc proto-oncogene proteinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingN-myc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificN-myc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificN-myc proto-oncogene proteinHomo sapiens (human)
DNA bindingN-myc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor activityN-myc proto-oncogene proteinHomo sapiens (human)
protein bindingN-myc proto-oncogene proteinHomo sapiens (human)
kinase bindingN-myc proto-oncogene proteinHomo sapiens (human)
protein dimerization activityN-myc proto-oncogene proteinHomo sapiens (human)
sequence-specific double-stranded DNA bindingN-myc proto-oncogene proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusMyc proto-oncogene proteinHomo sapiens (human)
nucleoplasmMyc proto-oncogene proteinHomo sapiens (human)
nucleolusMyc proto-oncogene proteinHomo sapiens (human)
cytoplasmMyc proto-oncogene proteinHomo sapiens (human)
Myc-Max complexMyc proto-oncogene proteinHomo sapiens (human)
RNA polymerase II transcription repressor complexMyc proto-oncogene proteinHomo sapiens (human)
chromatinMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complexMyc proto-oncogene proteinHomo sapiens (human)
nucleusN-myc proto-oncogene proteinHomo sapiens (human)
nucleoplasmN-myc proto-oncogene proteinHomo sapiens (human)
nucleolusN-myc proto-oncogene proteinHomo sapiens (human)
chromatinN-myc proto-oncogene proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's6 (50.00)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.48 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]